Download PDF
Nervenheilkunde 2009; 28(12): 883-888
DOI: 10.1055/s-0038-1628700
Schwabinger Neuro-Seminar
Schattauer GmbH

Schmerzen bei Parkinson-Syndromen

Pain in patients with parkinsonism
A. Ceballos-Baumann
1   Abteilung Neurologie und klinische Neurophysiologie, Neurologisches Krankenhaus München
› Author Affiliations
Further Information

Publication History

eingegangen am: 21 September 2009

angenommen am: 21 September 2009

Publication Date:
24 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Parkinson-Patienten klagen sehr häufig über Schmerzen und Missempfindungen. Dennoch werden Schmerzen bei Parkinson-Patienten häufig unterschätzt, fehldiagnostiziert und -behandelt. Opiate können die ParkinsonSymptomatik verschlechtern und Verwirrtheitszustände hervorrufen. Das therapeutische Vorgehen zielt zunächst auf eine Optimierung der dopaminergen Medikation, da Schmerzen meist mit der Akinese und dem Rigor zusammenhängen und mit motorischen Fluktuationen korrelieren. In einem weiteren Schritt kommt ein multimodaler Therapieansatz mit Analgetika, Physiotherapie und psychoedukativen Maßnahmen zur Anwendung.

Summary

Pain and sensory complaints are common among Parkinson’s disease patients. Despite its high prevalence in Parkinson’s disease the burden of pain is often underestimated, misdiagnosed and not correctly treated. Opiods can exacerbate rigidity and produce confusional states. Therapeutic strategies should firstly aim at a sufficient dopaminergic stimulation since pain is frequently linked to akinesia and rigidity and may fluctuate similarly to motor signs. Secondly, a multimodal approach including analgesics, physiotherapy and psychoeducation is frequently helpful to avoid chronification and impaired quality of life.

Schlüsselwörter

Schmerz - chronisches Schmerzsyndrom - idiopathisches Parkinson-Syndrom

Keywords

Pain - Parkinson’s disease - parkinsonism
 

  • Literatur

  • 1 Boecker H, Ceballos-Baumann AO, Weindl A, Bartenstein P, Siebner H, Faßbender T, Munz F, Schwaiger M, Conrad B. A PET activation study of sensory processing in Parkinson´s disease and Huntington´s disease. Brain 1999; 122: 1651-65.
    CrossrefPubMedGoogle Scholar
  • 2 Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov Disord 1996; 11 (01) 53-8.
    CrossrefPubMedGoogle Scholar
  • 3 Brefel-Courbon C, Grolleau S, Thalamas C, Bourrel R, Allaria-Lapierre V, Loi R, Micallef-Roll J, Lapeyre-Mestre M. Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain 2009; 141 (1–2) 14-8.
    CrossrefPubMedGoogle Scholar
  • 4 Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord 2005; 20 (12) 1557-63.
    CrossrefPubMedGoogle Scholar
  • 5 Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology 1989; 39 (10) 1309-14.
    CrossrefPubMedGoogle Scholar
  • 6 Cantello R, Aguggia M, Gilli M, Delsedime M, Riccio A, Rainero I, Mutani R. Analgesic action of methylphenidate on parkinsonian sensory symptoms. Mechanisms and pathophysiological implications. Arch Neurol 1988; 45 (09) 973-6.
    PubMedGoogle Scholar
  • 7 Ceballos-Baumann A, Gündel H. Bewegungsstörungen. In: Henningsen P, Gündel H, CeballosBaumann A. (ed.) Neuropsychosomatik. Stuttgart: Schattauer; 2006
    Google Scholar
  • 8 Ceballos-Baumann AO. Idiopathisches ParkinsonSyndrom: Grundlagen, Medikamente, Therapieeinleitung. In: Ceballos-Baumann AO, Conrad B. (Ed.) Bewegungsstörungen in der Neurologie. 2 Auflage. Stuttgart: Thieme; 2005
    Google Scholar
  • 9 Colosimo C, Salvatori FM. Injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 2009; 24 (02) 316-7.
    PubMedGoogle Scholar
  • 10 Decina P, Mukherjee S, Caracci G, Harrison K. Painful sensory symptoms in neuroleptic-induced extrapyramidal syndromes. Am J Psychiatry 1992; 149 (08) 1075-80.
    CrossrefPubMedGoogle Scholar
  • 11 Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol 1993; 33 (05) 490-3.
    CrossrefPubMedGoogle Scholar
  • 12 Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord. 2009 Jul 30. Epub ahead of print..
    Google Scholar
  • 13 Ford B. Pain in Parkinson’s disease. Clin Neurosci 1998; 05 (02) 63-72.
    CrossrefPubMedGoogle Scholar
  • 14 Ford B, Louis ED, Greene P, Fahn S. Oral and genital pain syndromes in Parkinson’s disease. Mov Disord 1996; 11 (04) 421-6.
    CrossrefPubMedGoogle Scholar
  • 15 Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson’s disease. Mov Disord 1986; 01 (01) 45-9.
    CrossrefPubMedGoogle Scholar
  • 16 Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45 (04) 712-7.
    CrossrefPubMedGoogle Scholar
  • 17 Indaco A, Carrieri PB. Amitriptyline in the treatment of headache in patients with Parkinson’s disease: a double-blind placebo-controlled study. Neurology 1988; 38 (11) 1720-2.
    CrossrefPubMedGoogle Scholar
  • 18 Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon?. J Neurol Neurosurg Psychiatry 1988; 51 (12) 1503-7.
    CrossrefPubMedGoogle Scholar
  • 19 Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord 2009; 24 (08) 1233-7.
    CrossrefPubMedGoogle Scholar
  • 20 Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O. Chronic pain in Parkinson’s disease: The cross-sectional French DoPaMiP survey. Mov Disord 2008; 23 (10) 1361-9.
    CrossrefPubMedGoogle Scholar
  • 21 Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord 1995; 10 (03) 333-6.
    CrossrefPubMedGoogle Scholar
  • 22 Polo KB, Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol 1994; 35 (02) 237-9.
    CrossrefPubMedGoogle Scholar
  • 23 Putzki N, Maschke M, Drepper J, Diener HC, Timmann D. Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson’s disease. J Neurol 2002; 249 (07) 824-8.
    CrossrefPubMedGoogle Scholar
  • 24 Riley D, Lang AE, Blair RDG, Birnbaum A, Reid B. Frozen shoulder and other shoulder abnormalities in Parkinson´s disease. J Neurol Neurosurg Psych 1988; 52: 63-66.
    Google Scholar
  • 25 Schmidt WJ, Schuster G, Wacker E, Pergande G. Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 1997; 327 (01) 1-9.
    CrossrefPubMedGoogle Scholar
  • 26 Schott GD. Pain in Parkinson’s disease. Pain 1985; 22 (04) 407-11.
    CrossrefPubMedGoogle Scholar
  • 27 Schwarz M, Nolden-Koch M, Purr J, Pergande G, Block F. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J Neural Transm Gen Sect 1996; 103 (05) 581-90.
    CrossrefPubMedGoogle Scholar
  • 28 Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976; 26 (05) 423-9.
    CrossrefPubMedGoogle Scholar
  • 29 Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006; 29 (06) 312-21.
    CrossrefPubMedGoogle Scholar
  • 30 Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008; 14 (03) 205-212.
    CrossrefPubMedGoogle Scholar
  • 31 Starkstein SE, Preziosi TJ, Robinson RG. Sleep disorders, pain, and depression in Parkinson’s disease. Eur Neurol 1991; 31 (06) 352-5.
    CrossrefPubMedGoogle Scholar
  • 32 Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, Fiaschi A, Martino D, Defazio G. Pain and motor complications in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77 (07) 822-5.
    CrossrefPubMedGoogle Scholar
  • 33 Tiple D, Fabbrini G, Colosimo C, Ottaviani D, Camerota F, Defazio G, Berardelli A. Camptocormia in Parkinson disease: an epidemiological and clinical study. J Neurol Neurosurg Psychiatry 2009; 80 (02) 145-8.
    CrossrefPubMedGoogle Scholar
  • 34 Tison F, Wiart L, Guatterie M, Fouillet N, Lozano V, Henry P, Barat M. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord 1996; 11 (06) 729-32.
    CrossrefPubMedGoogle Scholar
  • 35 Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord 2001; 16 (02) 252-7.
    CrossrefPubMedGoogle Scholar
  • 36 von Coelln R, Raible A, Gasser T, Asmus F. Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 2008; 23 (06) 889-92.
    CrossrefPubMedGoogle Scholar